Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

GREY:CLAZF - Post Discussion

Claritas Pharmaceuticals Inc > and what happened now
View:
Post by mavericks2020 on Apr 05, 2021 9:54pm

and what happened now

eom
Comment by Scotty on Apr 05, 2021 10:07pm
Inevitability.
Comment by whisky11 on Apr 05, 2021 10:08pm
=mavericks2020]eom whisky11: the price for license to develop and commercialize R-107 went up. Usually it's because Kaly got into agreement I, don't know what kind is it money or Government contract ,anyways look like the sign of success. Kaly got to pay more  money to Salzman group only when they achieve profit  or another stage of production, they call it a marker. Original ...more